Management of Progressive Vasculitis in Asymptomatic IgA Nephropathy
For an asymptomatic patient with IgA nephropathy and progressive vasculitis, you must initiate immunosuppressive therapy with glucocorticoids, and in cases with rapidly progressive glomerulonephritis (RPGN) or extensive crescentic disease, add cyclophosphamide. 1, 2
Risk Stratification and Treatment Threshold
The term "progressive vasculitis" in IgAN indicates active glomerular inflammation with vasculitic/crescentic lesions, which carries a poor prognosis regardless of symptoms. The 2026 IgA vasculitis guidelines emphasize that severe kidney involvement includes RPGN and rapid eGFR decline (>30% in 1-2 weeks), both requiring urgent intervention 1. Even if the patient is currently asymptomatic, progressive disease mandates treatment.
Key indicators for treatment:
- Proteinuria >0.5 g/g persisting for 2-4 weeks
- eGFR decline >30% over 1-2 weeks
- Crescentic glomerulonephritis on biopsy (if performed)
- **eGFR <60 ml/min/1.73 m²** with proteinuria >0.5 g/g 1
Treatment Algorithm
First-Line Therapy: Glucocorticoids
Initiate glucocorticoids immediately for IgA vasculitis with kidney involvement showing poor prognostic factors 1. The 2025 KDIGO guideline for IgAN recommends:
- Methylprednisolone 0.4 mg/kg/day (maximum 32 mg/day) for 2 months
- Taper by 4 mg/day each month for total duration of 6-9 months
- Mandatory antimicrobial prophylaxis against Pneumocystis jirovecii
- Antiviral prophylaxis for hepatitis B carriers
- Gastroprotection and bone protection 3
Rapidly Progressive Disease: Add Cyclophosphamide
For RPGN or extensive crescentic disease, combine cyclophosphamide with glucocorticoids 1, 2. The evidence shows:
- Cyclophosphamide 2 mg/kg/day for 3 months, followed by azathioprine 100 mg/day for maintenance 4
- This combination heals vasculitic lesions and arrests glomerular scarring progression
- Plasma exchange can be considered for refractory cases 1
A retrospective study demonstrated that steroids plus immunosuppressants reduced acute vasculitic lesions from median 17.4% to 0% of glomeruli, with stabilization of renal function in most patients 4.
Supportive Therapy (Concurrent with Immunosuppression)
Optimize RAS blockade as first-line supportive therapy:
Add SGLT2 inhibitor for patients at risk of progressive kidney function loss 3
Consider sparsentan (dual endothelin-angiotensin receptor antagonist) where approved, which replaces rather than supplements RAS inhibition 3
Critical Caveats
Glucocorticoid Toxicity Risk
Toxicity increases significantly with:
- eGFR <30 ml/min/1.73 m²
- Diabetes or prediabetes
- Obesity
- Latent infections (tuberculosis, viral hepatitis)
- Active peptic ulceration
- Uncontrolled psychiatric illness
- Osteoporosis or cataracts 3
However, the presence of progressive vasculitis generally outweighs these risks in terms of preventing kidney failure.
Kidney Biopsy Indication
If not already performed, kidney biopsy is indicated when:
- Rapid worsening of kidney function (>30% eGFR decline in 1-2 weeks)
- Persistent proteinuria >0.5 g/g for 2-4 weeks
- Diagnostic uncertainty regarding IgA vasculitis nephritis 1
The biopsy should be classified using the Oxford MEST-C score to guide prognosis 1.
Emerging Therapies
For refractory or aggressive disease, sequential complement inhibition combined with BAFF/APRIL blockade has shown promise in case reports, with substantial proteinuria reduction and kidney function stabilization 5. This represents a potential salvage option when conventional therapy fails.
What NOT to Use
The 2025 KDIGO guideline explicitly does not recommend:
- Antiplatelet agents
- Anticoagulants
- Azathioprine (except as maintenance after cyclophosphamide)
- Calcineurin inhibitors
- Rituximab
- Fish oil 3
Monitoring Strategy
After initiating treatment:
- Repeat kidney biopsy at end of treatment course (typically 12 months) to assess healing of vasculitic lesions 4
- Monitor serum creatinine at 12 and 24 months
- Track proteinuria reduction as marker of treatment response
- Be aware that 4 patients in the retrospective cohort developed ESRD between 24-81 months despite initial response, indicating need for long-term surveillance 4